Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 20/20 | 0.54 |
| ▸ | LCK | P06239 | 10/20 | 0.48 |
| ▸ | MET | P08581 | 9/20 | 0.48 |
| ▸ | TEK | Q02763 | 9/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2434058 | 0.93 | KDR (0.53) | KDRLCKMETTEK | |
| SCHEMBL2435014 | 0.91 | KDR (0.52) | KDRLCKMETTEK | |
| SCHEMBL2435819 | 0.84 | KDR (0.53) | KDRLCKMETTEK | |
| SCHEMBL2710189 | 0.82 | KDR (0.58) | KDRLCKMETTEK | |
| SCHEMBL2437252 | 0.81 | RAF1 (0.53) | KDRLCKMETTEK | |
| SCHEMBL2436659 | 0.78 | CDK2 (0.72) | KDRLCKMETTEK | |
| SCHEMBL2436643 | 0.77 | CDK8 (0.61) | KDRLCKMETTEK | |
| SCHEMBL274235 | 0.77 | KDR (0.51) | KDRLCKMETTEK | |
| SCHEMBL2433982 | 0.77 | KDR (0.58) | KDRLCKMETTEK | |
| SCHEMBL2432193 | 0.75 | KDR (0.56) | KDRLCKMETTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | SUMMIT CORPORATION PLC (GB) | 2011-09-29 | — | — | US | disclosed |
| US-8026247-B2 | Bicyclic amides as kinase inhibitors | NOVARTIS AG (CH) | 2011-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | GAA, MAN2B1, GBA1 | KDR 4875/4885LCK 3663/4885MET 4648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.